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Background: Muscle invasive bladder cancer (MIBC) is often lethal and non-MIBC (NMIBC) can recur and progress,
yet prognostic markers are currently inadequate. SAM68, a member of RNA-binding proteins, has been reported to
contribute to progression of other cancers. The aim of this study is to investigate the potential utility of SAM68 in
the progression and prognosis of bladder cancer.
Methods: Quantitative PCR and immunohistochemistry were utilized to examine the expression of SAM68 in ten
pairs of MIBC and adjacent normal bladder urothelium, and eight pairs of MIBC and non-MIBC (NMIBC) tissues from
the same patient. Moreover, SAM68 protein expression level and localization were examined by immunohistochemistry
in 129 clinicopathologically characterized MIBC samples. Prognostic associations were determined by multivariable
analysis incorporating standard prognostic factors.
Results: SAM68 expression was elevated in MIBC tissues compared with adjacent normal bladder urothelium, and was
increased at both transcriptional and translational levels in MIBC tissues compared with NMIBC tissues of the same
patient. For MIBC, high expression and nucleus-cytoplasm co-expression of SAM68 were associated with higher T-stage,
higher N-stage and worse recurrence-free survival. Five-year recurrence-free survival was 80% and 52.9% for MIBC
patients with low and high SAM68 expression, respectively (p = 0.001). SAM68 nucleus-cytoplasm co-expression
associated with worse 5-year recurrence-free survival rate (49.2%) than SAM68 expression confined to the nucleus
(82.5%) or cytoplasm (75.5%) alone. On multivariable analysis SAM68 expression level, SAM68 nucleus-cytoplasm
co-expression, T-stage, and N-stage were all independent prognostic factors for recurrence-free survival of MIBC patients.
Conclusions: SAM68 expression is increased in MIBC when compared to normal urothelium and NMIBC, and appears to
be a potentially useful prognostic marker for MIBC.
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Bladder cancer is the fourth most-common malignancy
in men, accounting for 7% of all cancer cases. In 2014
there will be 74,690 new cases of bladder cancer in the
USA alone, leading to 15,580 cancer-related deaths [1].
About 25% of bladder cancers are muscle invasive
(MIBC) at presentation [2,3], and such patients are at
high risk of cancer death even after intensive treatment,
with a five-year survival rate of 33% and 5.4% for re-
gional and distal metastasis MIBC, respectively [4].* Correspondence: zhoufj@sysucc.org.cn
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unless otherwise stated.Approximately 1/3 patients have cancer recurrence after
cystectomy even with adjuvant chemotherapy [5]. Al-
though altered expression of oncogenes, tumor suppres-
sors, and other markers have been found in bladder
cancer [6], the prognostic utility of currently available
biomarkers remains limited, and they are not routinely
incorporated into clinical practice. The identification of
novel biomarkers involved in the progression of bladder
cancer would greatly facilitate patient management.
SAM68 (Src-associated in mitosis, 68 kDa) is a
member of the STAR (signal transduction and activa-
tion of RNA) family of RNA-binding proteins [7],
and has shown potential as a biomarker for malignancy
[8-11]. SAM68 proteins have an hnRNP K homology
domain (KH domain) that locates within a larger GSGThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cificity and high-affinity binding to RNA [7,12]. This
multimodular structure allows SAM68 protein to exert
different functions in the cell, including regulation of the
cell cycle, proliferation, and apoptosis. SAM68 has been
reported to associate with progression and/or prognosis
for a variety of malignancies, including renal cell carcin-
oma [8], prostate cancer [9], cervical cancer [10] and
breast cancer [11]. For example, increased expression
and cytoplasmic localization of SAM68 correlated with
clinical outcomes and prognosis for patients with breast
cancer. An in vitro study revealed that down-regulation
of SAM68 in breast cancer cells inhibited cell prolifera-
tion by blocking the transition from G1 to S phase, and
the Akt/GSK-3β signaling and FOXO/p21/p27 pathway
appeared to be involved [11]. In early-stage cervical can-
cer, increased expression of SAM68 associated with
lymph node metastasis apparently by promoting cellular
motility and invasion, again through the Akt/ GSK-3β
pathway [10]. In the current study, we explore the poten-
tial utility of SAM68 expression and localization in hu-
man bladder cancer, and report correlations with clinical
outcomes, progression and prognosis.
Methods
Patients and tissue specimens
Patient consent and approval from the Sun Yat-sen
University Cancer Center Institutional Review Board
were obtained for the use of these clinical materials for
research purposes. Ten pairs of MIBC tissue specimens
and corresponding non-tumorous specimens were ob-
tained from patients with bladder cancer who underwent
radical cystectomy at the Cancer Center of the Sun
Yat-sen University (Guangzhou, P. R. China). Eight paired
of non-muscle invasive (NMIBC) and MIBC tissues from
the same patient were obtained from TURBT and radical
cystectomy, respectively. All excised tissues were ob-
tained within 1 h after surgery and were immediately
placed in liquid nitrogen until further analysis. Immuno-
histochemistry analyses were performed on 129 paraffin-
embedded radical cystectomy samples, which were
histologically diagnosed as MIBC at the Cancer Center,
Sun Yat-sen University, between 2000 and 2008. Tumor-
node-metastasis (TNM) staging was determined accord-
ing to the 2010 American Joint Committee on Cancer
TNM classification of bladder cancer [13]. The detail of
patients’ information are summarized in Table 1. The
median follow-up period for this cohort of patients was
32 months (range, 6-104 months). During the follow-up
period, 35 patients had tumor recurrence.
RNA extraction and quantitative PCR
Total RNA from tumor and adjacent non-tumorous tis-
sues was extracted using the TRIzol reagent (Invitrogen)according to the manufacturer's instructions. Quantita-
tive polymerase chain reaction (PCR) was performed
according to standard methods as described previously
[8]. PCR primers and probes were designed with the use
of Primer Express Software v.2.0 (Applied Biosystems) as
described previously [8].
Immunohistochemistry
Immunohistochemistry (IHC) was performed to study
altered SAM68 protein expression levels in 129 human
MIBC tissues, as well as the ten pairs of MIBC tissue
specimens and corresponding non-tumorous specimens,
and eight paired of NMIBC and MIBC tissues. In brief,
4 μm-thick tissue sections were incubated with poly-
clonal rabbit antibody against SAM68 (1:200; Abgent) at
4°C overnight. Before incubation with the primary anti-
body, the sections were treated for antigen retrieval with
ethylene diamine tetraacetic acid buffer followed by
heating in a microwave oven. For negative controls, the
rabbit anti-SAM68 antibody was restored with normal
nonimmune serum. After washing, tissue pieces were
treated with biotinylated anti-rabbit secondary antibody
(Zymed), followed by further incubation with streptavi-
din -horseradish peroxidase complex (Zymed). Tissue
sections were then immersed in 3,3′-diaminobenzidine
and counterstained with 10% Mayer's hematoxylin,
dehydrated, and mounted.
The degree of immunostaining of paraffin-embedded sec-
tions was reviewed and scored independently by two ob-
servers based on the proportion of positively-stained tumor
cells and the intensity of staining. The method has been in-
troduced in detail previously [8]. The staining index was
calculated as the product of the staining intensity score and
the proportion of positive tumor cells. Using this method of
assessment, we evaluated SAM68 expression in MIBC tis-
sues by determining the staining index, with scores of 0, 1,
2, 3, 4, 6, 8, 9, and 12. SAM68 threshold values were chosen
on the basis of a measure of heterogeneity with the log-
rank test statistical analysis with respect to recurrence-free
survival. An optimal threshold value was identified: a stain-
ing index score >6 was considered to show high SAM68
expression, whereas a staining index score <4 was consid-
ered to represent low SAM68 expression.
Statistical analysis
The relationship between SAM68 expression and clini-
copathological characteristics was analyzed by the chi-
square and Fisher’s exact tests. Survival curves between
subgroups that were divided according to SAM68 ex-
pression levels and localizations were drawn with the
use of the Kaplan-Meier method, and significant differ-
ences among subgroups were compared by the log-rank
test. Survival data were evaluated using univariate
and multivariable Cox regression analyses. In all cases,
Table 1 Correlation between clinicopathological features and SAM68 expression in MIBC patients
Characteristics n SAM68 χ2 test
P-value
n SAM68 χ2 test
P-valueLow High Nucleus Cytoplasm Nucleus and cytoplasm
co-expression
Age (years) <60 63 32(50.8) 31(49.2) 0.292 62 25(40.3) 12(19.4) 25(40.3) 0.362
≥60 66 27(40.9) 39 (59.1) 61 18(29.5) 11 (18.0) 32 (52.5)
Gender Male 116 55(47.4) 61 (52.6) 0.380 110 40(36.4) 21 (19.1) 49 (44.5) 0.497
Female 13 4(30.8) 9 (69.2) 13 3(23.1) 2 (15.4) 8 (61.5)
pT stage T2 80 43(53.8) 37(46.3) 0.028 77 30(39.0) 18(23.4) 29(37.7) 0.035
T3~4 49 16(32.7) 33(67.3) 46 13(28.3) 5(10.9) 28(60.9)
pN stage N− 111 55(49.5) 56(50.5) 0.041 105 39(37.1) 22(21.0) 44(41.9) 0.050
N+ 11 4(22.2) 14(77.8) 18 4(6.3) 1(5.6) 13(72.2)
Grade Low 32 12(37.5) 20(62.5) 0.312 31 11(35.5) 4(12.9) 16(51.6) 0.608
High 97 47(48.5) 50(51.5) 92 32(34.8) 19(20.7) 41(44.6)
Smoking history Yes 68 29(42.6) 39(57.4) 0.483 65 23(35.4) 12(18.5) 30(46.2) 0.994
No 61 30(49.2) 31(50.8) 58 20(34.5) 11(19.0) 27(46.6)
Gross hematuria Yes 102 43(42.2) 59(57.8) 0.132 97 32(33.0) 19(49.5) 46(47.4) 0.664
No 27 16(59.3) 11(40.7) 26 11(42.3) 4(15.4) 11(42.3)
UIS Yes 18 8(44.4) 10(55.6) 1.000 17 5(29.4) 2(11.8) 10(58.8) 0.511
No 111 51(45.9) 60(54.1) 106 38(35.8) 21(19.8) 47(44.3)
Tumor multiplicity Yes 70 34(48.6) 36(51.4) 0.595 66 18(27.3) 16(24.2) 32(48.5) 0.087
No 59 25(42.4) 34(57.6) 57 25(43.9) 7(12.3) 25(43.9)
Adjuvant chemotherapy Yes 39 13(33.3) 26(66.7) 0.083 37 13(35.1) 4(10.8) 20(54.1) 0.295
No 90 46(51.1) 44(48.9) 86 30(34.9) 19(22.1) 37(43.0)
Tumor recurrence Yes 35 9(25.7) 26(74.3) 0.006 32 6(18.8) 5(15.6) 21(65.6) 0.031
No 94 50(53.2) 44(46.8) 91 37(40.7) 18(19.8) 36(39.6)
MIBC: muscle invasive bladder cancer; UIS: urinary irritation symptoms.
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statistical analyses were conducted using the SPSS v.13.0
statistical software package (SPSS, Chicago, IL, USA).
Results
The expression of SAM68 in paired of MIBC tissues and
adjacent normal bladder urothelium
To determine the expression of SAM68 in MIBC tissues,
quantitative PCR analyses were conducted on ten
matched pairs of bladder cancer tissues and adjacent,
nontumorous bladder urothelium from the same patient.
As shown in Figure 1, all the ten bladder cancer tissues
showed up-regulated SAM68 mRNA expression, when
compared with their adjacent bladder urothelium. IHC
analysis further confirmed this result in the translation
level (Figure 1B). These data suggests that SAM68 ex-
pression was elevated in human MIBC.
The expression of SAM68 in paired of NMIBC and
MIBC tissues
To explore the role of SAM68 in bladder cancer pro-
gression, we analyzed eight MIBC patients with a historyof NMIBC, who underwent radical cystectomy for recur-
rent tumor infiltrated into or beyond muscularis propria.
Paired of NMIBC and MIBC were obtained from
TURBT and radical cystectomy, respectively, of the same
patient. The results indicated that SAM68 was markedly
up-regulated at both transcriptional and translational
levels in MIBC tissues compared with NMIBC tissues by
quantitative PCR and IHC (Figure 2A and B). These
findings suggested that bladder cancer developing from
NMIBC to MIBC may be accompanied with SAM68
expression level ascending.
The expression of SAM68 in 129 MIBC tissues from
radical cystectomy
To study the clinicopathological significance of SAM68
in MIBC, we examined the SAM68 protein expression
levels in 129 paraffin-embedded, archived MIBC, from
radical cystectomy, with long term follow-up data. The
IHC results are summarized in Table 1. SAM68 protein
was detected in 123 out of 129 (95.3%) human MIBC
samples, in which 70(54.3%) showed high expression of
SAM68 protein and 59(45.7%) showed low expression of
Figure 1 Expression of SAM68 mRNA and protein in paired muscle invasive bladder cancer tissues and adjacent non-carcinoma tissues. (A) Quantitative
PCR showed the mRNA level of SAM68 was much higher in bladder cancer tissues compared with adjacent non-carcinoma tissues. Expression levels
were normalized for GAPDH. Error bars represent the standard deviation (SD) calculated from three parallel experiments. (B) Immunohistochemistry
analysis was performed to detect the SAM68 protein level in tumor (T) and non-carcinoma tissues (N) from the same patient.
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SAM68 protein, there were three types of expression
pattern, including nucleus expression, cytoplasm expres-
sion and nucleus-cytoplasm co-expression (Figure 3B).
43 cases (35.0%) had SAM68 expression in nucleus, 23
cases (17.8%) in cytoplasm and 57 cases (46.3%) had
SAM68 expressed in both nucleus and cytoplasm.
High expression and nucleus-cytoplasm co-expression of
SAM68 were associated with clinical features and
recurrence-free survival
To determine the association of SAM68 expression and
clinical features and recurrence-free survival of MIBC,
χ2 test and survival analysis with long-rank test were
performed. As shown in Table 1, high expression and
nucleus-cytoplasm co-expression of SAM68 were corre-
lated with the T stage (p = 0.028, and p = 0.035), N stage(p = 0.041, and p = 0.050) and recurrence status (p = 0.006,
and p = 0.031). The Kaplan-Meier survival analysis indi-
cated that patients who had high SAM68 expression
levels had worse recurrence-free survival than those
with low SAM68 expression. The low SAM68 expres-
sion group had a cumulative 5-year recurrence- free
survival rate of 80.0% (95% confidence interval [CI],
0.680-0.919), whereas the high SAM68 expression
group only had 52.9% (95% CI, 0.384-0.674) (Figure 4A).
Patients with SAM68 nucleus-cytoplasm co-expression
had lower 5-year recurrence- free survival rate (49.2%)
than those with SAM68 expressed in nucleus (82.5%) or
cytoplasm (75.5%). However, the difference of recurrence-
free survival curve between SAM68 nucleus group and
cytoplasm group is not significant (Figure 4B). In addition,
the multivariable analysis revealed that SAM68 expression
level, nucleus-cytoplasm co-expression, accompanied with
Figure 2 Expression of SAM68 protein was increased when bladder tumor developed from non-muscle invasive to muscle invasive. (A) Increased
fold of SAM68 mRNA for muscle invasive tumor comparing to non-muscle invasive tumor from the same patient. (B) Immunohistochemistry study
confirmed the expression of SAM68, in the protein level, was much higher in muscle invasive tumor samples than non-muscle invasive tumor from
the same patient. For each pair of sample, the left panel represents non-muscle invasive bladder cancer (NMIBC) sample obtained from transurethral
resection of bladder tumor and the right panel represents muscle invasive bladder cancer (MIBC) sample gained from radical cystectomy.
Zhang et al. BMC Cancer  (2015) 15:364 Page 5 of 8T stage, and N stage were independent prognostic factors
for the recurrence-free survival rate of MIBC patient
(Table 2). These results indicated that SAM68 has poten-
tial as a valuable prognostic marker for MIBC after radical
cystectomy.
Discussion
MIBC is typically managed with perioperative chemo-
therapy and radical cystectomy with extended pelvic
lymph node dissection [14], yet almost 50% of such pa-
tients will eventually succumb to disease progression
[14,15]. In addition, even for survivors, quality of life isFigure 3 Typical images showed the expression level and localization of S
showed the negative, low level and high level expression of SAM68 protein
expression according to the intracellular localization: nucleus expression, cy
400×; right panel: 800 × .often compromised due to the urinary diversion, erectile
dysfunction, or other functional concerns [16,17]. Avail-
ability of prognostic biomarkers would greatly improve
our management of patients with bladder cancer by
facilitating better patient selection and individualized
risk stratification. Previous efforts have focused primarily
on cell cycle regulators, but the clinical utility of cur-
rently available markers remains limited. For instance,
Margulis and colleagues [18] studied Ki-67, a marker of
proliferation, after radical cystectomy and reported an
independent association of high Ki-67 labeling index
with disease recurrence and cancer-specific mortality.AM68 protein as examined by immunohistochemistry (IHC). (A) Series
. Left panel: 200×; right panel: 400×. (B) Three types of SAM68
toplasm expression and nucleus-cytoplasm co-expression. Left panel:
Figure 4 Kaplan-Meier curves with log-rank test comparing recurrent free survival (RFS) in different subgroups (A) Bladder cancer patients with
low SAM68 expression (bold line) had a cumulative 5-year RFS rate of 80.0%, compared to 52.9% for patients with high SAM68 expression (dotted
line; p = 0.001). (B) Comparison of RFS curves between groups with different SAM68 intracellular localization. The RFS curves were similar between
SAM68 nucleus expression and cytoplasm expression groups (p = 0.539). However, the RFS was much worse in the nucleus-cytoplasm co-expression
group, no matter compared with nucleus expression group (p = 0.002) or cytoplasm expression group (p = 0.037).
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studies which investigated the role of increased p53 ex-
pression for predicting the prognosis of bladder cancer,
reporting an overall hazard ratio of 1.43 for predicting
mortality. However, due to the complicated biological
behavior of bladder cancer, none of these markers have
been widely used in clinical practice. Hence, there is still
a great need to identify novel predictive factors for blad-
der cancer.
In the current study, we evaluate SAM68 as a potential
prognostic marker for MIBC, and report for the first
time clinical and pathologic correlates for this malignancy.
Using immunohistochemistry, we found that MIBC pa-
tients with high expression or nucleus-cytoplasm co-
expression of SAM68 had lower recurrence-free survival
at 5 years. Multivariable analysis revealed that SAM68 ex-
pression level and nucleus-cytoplasm co-expression were
independent prognostic factors for recurrence-free sur-
vival, adding additional prognostic power above that
provided by T-stage and N-stage, which are the well-
established prognostic factors for this malignancy. Our




pT stage (T3 ~ 4 vs. T2) 4.445 2.221 ~ 8.896
pN stage (N+ vs. N−) 4.944 2.313 ~ 10.780
SAM68 level (High vs. low) 3.366 1.574 ~ 7.201
SAM68 Localization* 2.003 1.267 ~ 3.166
MIBC: muscle invasive bladder cancer; HR: hazard ratio; CI, confidence interval.
*nucleus-cytoplasm co-expression vs. expression in nucleus vs. expression in cytoplstratification after radical cystectomy that could prove to
be of clinical utility. In particular, patients with high ex-
pression or nucleus-cytoplasm co-expression of SAM68
may need adjuvant therapy and more intensive surveil-
lance. If identified on biopsy, SAM68 could potentially
influence decisions about neoadjuvant chemotherapy or
even less intensive alternative strategies, such as chemo-
radiation, although further studies will be required. In
addition, we found that bladder cancer developing from
NMIBC to MIBC may be associated with increased
SAM68 expression, which if validated in independent
and larger cohorts, might suggest a potential target
for therapeutics.
Our findings are consistent with recent data about
SAM68 as a tumor-promoter in other cancers [8,10,11,20],
although the mechanism of action is not well defined. Con-
sistent with this, we found that the expression level of
SAM68 was much higher in MIBC when compared to ad-
jacent normal bladder urothelium or NMIBC tissue from
the same patient. Furthermore high expression of SAM68
associated with worse clinicopathological parameters and
prognosis. These findings supported SAM68 as a potentialostic parameters in patients with MIBC: Cox-regression
Multivariate analysis
p Value HR 95% CI p Value
<0.001 2.308 1.047 ~ 5.089 0.038
<0.001 2.879 1.222 ~ 6.872 0.016
0.002 2.365 1.055 ~ 5.298 0.037
0.003 1.749 1.106 ~ 2.767 0.017
asm.
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effect cannot be excluded, and the biological basis for this
will require further investigation. In other cancers, the
function and mechanism of action of SAM68 in cancer
progression has been revealed to some degree. In LNCaP
prostate cancer cells, reduced expression of SAM68 altered
the expression of an important subset of genes involved in
proliferation and apoptosis, including Bcl2L1, Clusterin,
cdk2, cdk3, p16INK4, cyclin D1, Par-4, EGF and IGF-1
[21]. In breast cancer cells, silencing SAM68 resulted in
anti-proliferative effects that appeared to be due to up-
regulation of p21 and p27 and attenuation of Akt/GSK-3β
signaling [11]. Further studies will be required in bladder
cancer to determine if similar or alternate mechanisms of
action are operative.
Another interesting finding was that almost 50% of
MIBC cases demonstrated co-expression of SAM68 in
both the nucleus and cytoplasm, which associated with
advanced T and N stage and compromised recurrence-
free survival, and co-expression proved to be an inde-
pendent prognostic factor on multivariable analysis.
Although SAM68 was initially reported to be predomin-
antly localized to the nucleus [22,23], cytoplasmic
localization has also been observed in several human
cancers and has shown clinical significance, particularly
for breast cancer and early-stage cervical cancer [10,11].
Although the function and mechanism of SAM68 accu-
mulation within the cytoplasm remains unknown, sev-
eral hypotheses have been proposed. Some studies have
suggested that cytoplasmic SAM68 may associate with
polysomal mRNAs and enhance the translational effi-
ciency of eEF1, an elongation factor which has been
implicated in cellular transformation [21,24-26]. It is
particularly noteworthy in our study that the prognosis
was much worse in the nucleus and cytoplasm co-
expression group compared with expression isolated to
either the nucleus or cytoplasm, while the prognosis of
the latter two groups appeared to be similar. A possible
explanation for this phenomenon is that SAM68 causes
poor prognosis of bladder cancer by pulling two triggers in
both the nucleus and cytoplasm simultaneously, which
may act in a synergistic manner, although further research
will be required to study such potential mechanisms.
Although our study enrolled a large cohort of MIBC
patients, there are still some limitations. Firstly, this was
a retrospective study, and some bias is therefore inevit-
able. Secondly, the mechanism and function of the
accumulation of SAM68 in the cytoplasm were not in-
vestigated in this study. Thirdly, the role of high expres-
sion of SAM68 in bladder cancer cell progression has
not been illuminated. Finally, independent validation
with larger cohorts of patients will be required to more
definitively explore the potential value of SAM68 as a
biomarker for bladder cancer.Conclusions
In summary, our study suggests that SAM68 expression
is elevated in MIBC compared with normal urothelium
and NMIBC and may have potential as a prognostic
marker for MIBC. However, large scale prospective study
will be required to validate our findings, and further
studies regarding mechanisms of action are also
indicated.
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